Beyond Glycaemic Control: Efficacy and Safety of Newer Antidiabetic Agents in Patients with Cardiorenal Disease—A Narrative Review
Preprint
- 29 October 2026
- preprint
- Published by MDPI AG in Preprints.org
Abstract
Cardiovascular disease and chronic kidney disease are the leading causes of death in type 2 diabetes, and lowering glycated haemoglobin alone does not adequately address this risk. This narrative review summarises evidence on the glycaemic efficacy, cardiorenal outcomes and safety of sodium–glucose cotransporter-2 inhibitors (SGLT2i), glucagon-like peptide-1 receptor agonists (GLP-1 RAs), the dual glucose-dependent insulinotropic polypeptide/GLP-1 receptor agonist tirzepatide, dipeptidyl peptidase-4 inhibitors and once-weekly basal insulins, with attention to the Gulf region. PubMed/MEDLINE, ScienceDirect and Google Scholar were searched for trials, meta-analyses and guidelines published between 2015 and 2026. SGLT2i provide the most consistent reductions in heart failure hospitalisation and kidney disease progression, irrespective of diabetes status. GLP-1 RAs reduce major adverse cardiovascular events, stroke and kidney outcomes. Tirzepatide offers the greatest glycaemic and weight benefits, with cardiovascular protection comparable to an established GLP-1 RA. Dipeptidyl peptidase-4 inhibitors and weekly insulins are largely cardiorenal-neutral. Combining SGLT2i and GLP-1 RAs may provide additive protection. In the Middle East and North Africa, which has the highest diabetes prevalence worldwide, use of these organ-protective agents remains low. Therapy should be selected according to comorbidity, giving organ protection the same priority as glycaemic control.Keywords
All Related Versions
This publication has 90 references indexed in Scilit:
- Safety and Efficacy of Semaglutide in Patients With Chronic Kidney Disease, With or Without Type 2 Diabetes: A Systematic Review and Meta‐AnalysisEndocrinology, Diabetes & Metabolism, 2025
- The Expanding Scope of GLP-1 Receptor Agonists: Six Uses Beyond DiabetesCurrent Atherosclerosis Reports, 2025
- Is There a Role for SGLT2 Inhibitors in Patients with End-Stage Kidney Disease?Current Hypertension Reports, 2024
- 2024 Update in Heart FailureESC Heart Failure, 2024
- Recommendations for Early and Comprehensive Management of Type 2 Diabetes and Its Related Cardio-Renal ComplicationsDiabetes Therapy, 2022
- Updated Meta-Analysis Assessing the Cardiovascular Efficacy of TirzepatideThe American Journal of Cardiology, 2022
- Dipeptidyl peptidase-4 inhibitors, glucagon-like peptide 1 receptor agonists and sodium-glucose co-transporter-2 inhibitors for people with cardiovascular disease: a network meta-analysisCochrane Database of Systematic Reviews, 2021
- The efficacy and safety of novel classes of glucose-lowering drugs for cardiovascular outcomes: a network meta-analysis of randomised clinical trialsDiabetologia, 2021
- Type II diabetes mellitus: a review on recent drug based therapeuticsBiomedicine & Pharmacotherapy, 2020
- Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal RiskJAMA, 2019